ArticlePhysiological research2026
Sodium Selenite Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension by Upregulating GPX3 and Ameliorating Vascular Remodeling.
Article in Physiological research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Selenium deficiency is implicated in pulmonary arterial hypertension (PAH). This study investigated the effects of sodium selenite (SSE) on PAH and its underlying mechanisms. In a monocrotaline-induced PAH rat model, SSE treatment significantly improved right ventricular systolic pressure (RVSP), mean pulmonary arterial pressure (mPAP), and vascular remodeling. It reduced collagen deposition and partially restored the expression of Collagen 1 and SM22alpha. SSE upregulated glutathione peroxidase 3 (GPX3) expression and attenuated oxidative stress, as evidenced by enhanced SOD activity and decreased MDA levels. In vitro, SSE inhibited H?O? and angiotensin II-induced proliferation, oxidative stress, and phenotypic switching in pulmonary artery smooth muscle cells (PASMCs), while upregulating GPX3 at both mRNA and protein levels. These findings demonstrate that SSE alleviates PAH by enhancing GPX3-mediated antioxidant defense and suppressing vascular remodeling, supporting its potential as a therapeutic strategy for PAH.
Indexed as
Identifiers
42187509PMC13225451What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.